These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38693616)

  • 1. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.
    Sasabe E; Tomomura A; Yamamoto T
    J Oral Pathol Med; 2024 May; 53(5):310-320. PubMed ID: 38693616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidermal growth factor/epidermal growth factor receptor signaling blockage inhibits tumor cell-derived exosome uptake by oral squamous cell carcinoma through macropinocytosis.
    Sasabe E; Tomomura A; Liu H; Sento S; Kitamura N; Yamamoto T
    Cancer Sci; 2022 Feb; 113(2):609-621. PubMed ID: 34874595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.
    Kondo Y; Suzuki S; Ono S; Goto M; Miyabe S; Ogawa T; Tsuchida H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsa_circ_0005379 regulates malignant behavior of oral squamous cell carcinoma through the EGFR pathway.
    Su W; Wang Y; Wang F; Sun S; Li M; Shen Y; Yang H
    BMC Cancer; 2019 Apr; 19(1):400. PubMed ID: 31035951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma.
    Onda M; Ota A; Ito K; Ono T; Karnan S; Kato M; Kondo S; Furuhashi A; Hayashi T; Hosokawa Y; Kazaoka Y
    Cancer Med; 2023 Aug; 12(15):16416-16430. PubMed ID: 37341071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
    Ma L; Qin N; Wan W; Song S; Hua S; Jiang C; Li N; Huang L; Gao X
    Am J Physiol Cell Physiol; 2024 Feb; 326(2):C362-C381. PubMed ID: 38105756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.
    Zhang W; Pang Q; Zhang X; Yan C; Wang Q; Yang J; Yu S; Liu X; Pan Y; Yuan Z; Wang P; Xiao Z
    Cancer Sci; 2017 Apr; 108(4):590-597. PubMed ID: 28192623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
    Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
    Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
    Lin MC; Huang MJ; Liu CH; Yang TL; Huang MC
    Oral Oncol; 2014 May; 50(5):478-84. PubMed ID: 24582885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
    Cai Z; Hao XY; Liu FX
    Arch Oral Biol; 2018 May; 89():20-25. PubMed ID: 29407635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ephrin-B2 reverse signaling regulates progression and lymph node metastasis of oral squamous cell carcinoma.
    Sasabe E; Tomomura A; Tomita R; Sento S; Kitamura N; Yamamoto T
    PLoS One; 2017; 12(11):e0188965. PubMed ID: 29190834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
    Yin P; Cui S; Liao X; Yao X
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor protein D54 is a negative regulator of extracellular matrix-dependent migration and attachment in oral squamous cell carcinoma-derived cell lines.
    Mukudai Y; Kondo S; Fujita A; Yoshihama Y; Shirota T; Shintani S
    Cell Oncol (Dordr); 2013 Jun; 36(3):233-45. PubMed ID: 23529586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
    Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
    J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumol Exerts Antitumor Effect via Inhibiting EGFR-Akt-Mcl-1 Signaling.
    Li XY; Gao F; Wang XC; Liu LL; Gan Y; Han SZ; Zhou L; Li W; Li M
    Am J Chin Med; 2023; 51(3):741-760. PubMed ID: 36869017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulated circ_0002141 facilitates oral squamous cell carcinoma progression via the miR-1231/EGFR axis.
    Wangzhou K; Lu Z; Lai Z; Fu W; Liu C; Tan Y; Hao C
    Oral Dis; 2023 Apr; 29(3):902-912. PubMed ID: 34739167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin-α5 promoted the progression of oral squamous cell carcinoma and modulated PI3K/AKT signaling pathway.
    Fan QC; Tian H; Wang Y; Liu XB
    Arch Oral Biol; 2019 May; 101():85-91. PubMed ID: 30909080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.
    Iwase M; Takaoka S; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M
    Oral Oncol; 2008 Apr; 44(4):361-8. PubMed ID: 17689285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.